Key result
TAVR shows no difference versus surgery for composite outcomes in low-risk patients at five years.
Why the study?
Does Transcatheter Aortic-Valve Replacement (TAVR) improve primary composite outcomes in low-risk patients with severe, symptomatic aortic stenosis compared to surgery?
Does Transcatheter Aortic-Valve Replacement (TAVR) improve primary composite outcomes in low-risk patients with severe, symptomatic aortic stenosis compared to surgery?
At five years, TAVR performs similarly to surgery regarding primary composite outcomes in low-risk patients with severe, symptomatic aortic stenosis.
No takes yet. Share an insight, caveat, or question.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“[The study] provides robust, long-term evidence supporting the use of balloon-expandable TAVR in appropriately selected low-risk patients and reinforces the current guideline recommendations.”
Supports TAVR as durable alternative to surgery in low-risk aortic stenosis; extends randomized evidence to 5 years.
Mack et al. (2023) studied this question. Transcatheter aortic-valve replacement (TAVR) showed no significant difference in primary composite outcomes compared to surgery in low-risk patients at five years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: